Our pipeline is focused on developing itolizumab as a potentially first-in-class treatment for multiple severe immuno-inflammatory disorders, including graft-versus-host disease, uncontrolled moderate to severe asthma and SLE / lupus nephritis.
Phase 1b / 2
Positive FDA response to Pre-IND briefing package; if successful may suffice for BLA filing
IND submission pending for global DBPC study
Positive interim data announced
Biocon completed a Phase 1 study in healthy volunteers in Australia.